REVB

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Revelation Biosciences Inc revenue for the last quarter amounts to -1.94M USD, increased 8.14 % YoY.

Revelation Biosciences Inc. EPS for the last quarter amounts to -1588901.00 USD, decreased -82.87 % YoY.

Revelation Biosciences Inc (REVB) has 8 emplpoyees as of January 09 2026.

Today REVB has the market capitalization of 5.33M USD.